Understanding how certain cells contribute to the formation of sacrococcygeal teratomas in newborns
Official title: Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
Funded at University of California, San Francisco · NIH-10929998 · Data updated 2026-11-12
This study is looking into how certain cells in babies can lead to the development of sacrococcygeal teratomas, which are the most common tumors in newborns, to help find better ways to treat and prevent these tumors.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $41,081 |
| NIH project number | 5F31CA284719-02 |
| Project ID | NIH-10929998 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are newborns diagnosed with sacrococcygeal teratomas or those at risk of developing them.
✕Less likely to help
Patients with other types of tumors or those outside the newborn age range may not benefit from this research.
What this research studies
This research investigates the origins of sacrococcygeal teratomas (SCTs), the most common tumors found in newborns, by examining specific embryonic cells that resist programmed cell death. The study utilizes advanced techniques, including human stem cells and innovative mouse models, to explore how these cells can revert to a state that promotes tumor growth. By analyzing the genetic and environmental factors involved, the research aims to uncover the mechanisms that lead to SCT formation and recurrence, ultimately seeking to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and potential new treatments for sacrococcygeal teratomas, reducing morbidity and mortality in affected newborns.
How similar studies have gone: While the specific approach of using human induced pluripotent stem cells in this context is novel, similar studies have shown promise in understanding tumor biology and developing targeted therapies.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Rojas, Ernesto Javier — University of California, San Francisco
- Study coordinator: Rojas, Ernesto Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.